Vaxcyte, Inc. 8-K

What Happened

• Vaxcyte, Inc. announced its financial results for the quarter and full year ended December 31, 2025 by issuing a press release on February 24, 2026. The press release is furnished as Exhibit 99.1 to the Form 8-K filed that day and is incorporated by reference. The disclosure was made under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Press release date: February 24, 2026 (Exhibit 99.1 to the Form 8-K).
• Reporting period covered: quarter and full year ended December 31, 2025 (quarterly results and full-year results).
• Filing treatment: Information is furnished under Item 2.02 and, per Item 9.01, Exhibit 99.1 is furnished (not “filed”) for purposes of Section 18 of the Exchange Act and is not automatically incorporated by reference into other filings.
• No additional financial figures or operational metrics were included in the Form 8-K beyond furnishing the press release.

Why It Matters

• Earnings and revenue announcements for Q4 and full-year 2025 provide investors with the company’s most recent quarterly results and annual performance snapshot; the press release is the primary source for those metrics and guidance, if any.
• The Form 8-K’s treatment (furnished, not filed) limits certain legal liabilities under Section 18, so investors should consult the full press release (Exhibit 99.1) and follow-up SEC filings for detailed financial figures, management commentary, and context for the results.